Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

11.71
-0.6600-5.34%
Pre-market: 11.780.0700+0.60%07:01 EDT
Volume:8.30M
Turnover:99.03M
Market Cap:1.64B
PE:-3.50
High:12.41
Open:12.08
Low:11.70
Close:12.37
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.37
T/O Rate:6.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.25
PE(LYR):-3.07

Loading ...

Intellia to present additional Phase 3 HAELO data for lonvo-z in hereditary angioedema at EAACI 2026

Reuters
·
Jun 01

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

Movement Alert|Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63

Market Focus
·
May 28

Stock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness

Stock Track
·
May 19

Stock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness

Stock Track
·
May 15

Intellia Therapeutics Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

High Growth Tech Stocks In The US For May 2026

Simply Wall St.
·
May 13

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

TIPRANKS
·
May 13

Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline

Simply Wall St.
·
May 13

Intellia Therapeutics Price Target Maintained With a $12.00/Share by Wedbush

Dow Jones
·
May 12

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
May 12

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

TIPRANKS
·
May 12

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

TIPRANKS
·
May 12

Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Intellia Therapeutics Q1 Loss Narrows, Revenue Falls

MT Newswires Live
·
May 11

Intellia Therapeutics Q1 net loss narrows on lower R&D spending

Reuters
·
May 11